ImmunoGen, Inc. Appoints David Johnston as Chief Financial Officer

  ImmunoGen, Inc. Appoints David Johnston as Chief Financial Officer

Business Wire

WALTHAM, Mass. -- December 30, 2013

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted
anticancer therapies using its industry leading antibody-drug conjugate (ADC)
technology, today announced the appointment of David Johnston as Executive
Vice President and Chief Financial Officer, effective today. Mr.Johnston
brings to ImmunoGen more than 30 years of experience in corporate finance,
including 15 years in senior financial functions at biotechnology companies,
as well as extensive experience in corporate planning. He reports to Daniel
Junius, President and Chief Executive Officer of ImmunoGen.

“I am delighted to have Dave join ImmunoGen,” commented Mr. Junius. “His depth
of experience in both senior financial positions and in corporate planning
makes Dave well-suited to help successfully advance the Company to our next
stages.”

Mr. Johnston joins ImmunoGen from AVEO Pharmaceuticals Inc., where he was the
CFO. Prior to joining AVEO in 2007, Mr. Johnston was Senior Vice President of
Finance, Corporate Planning and Analysis at Genzyme Corporation and, before
that, the VP Finance and CFO of Genzyme Biosurgery. Prior to joining Genzyme
in 1998, Mr. Johnston held financial, planning and analysis positions of
increasing responsibility at several major corporations. He holds a BS degree
from Washington and Lee University and an MBA from the University of Michigan.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC
technology uses a tumor-targeting engineered antibody to deliver one of
ImmunoGen's highly potent cancer-cell killing agents specifically to tumor
cells; the Company has also developed antibodies with anticancer activity of
their own. The most advanced compound with ImmunoGen’s ADC technology is
Roche’s Kadcyla^®, which is marketed in the US by Genentech and is also
gaining approvals internationally. Additional compounds are in clinical
testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer
HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found
at www.immunogen.com.

Kadcyla^® is a registered trademarks of Genentech, Inc., a member of the Roche
Group.

Contact:

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153